Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Gossamer Bio, Inc.NASDAQ: GOSS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $16.96M rose 71.5% year over year, ahead of the -55.4% change in trailing-twelve-month revenue. Sequentially, it rose 22.9% from the prior quarter.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $64.61M (+33.3%) for the fiscal year ending Dec 2026, a step up from the -57.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.96M+22.9% QoQ
- Last fiscal yearDec 2025
- $48.47M-57.7% YoY
- LTMMar 2026
- $55.54M-55.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +71.5% | -68.4% | -139.9 pp |
| 1 year | -57.7% | +33.3% | +91.0 pp |
| 3-year CAGR | — | +19.5% | — |
| 5-year CAGR | +41.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 48.47M USD
- Year-over-year change
- -57.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.47M | -57.7% |
| FY2024 | 2024-12-31 | 114.7M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 revenue of $55.54M is the 7th highest of the 9 companies compared; the peer median is $78.73M.
- Its year-over-year change of -55.4% is the 5th highest of 6, against a peer median of +47.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $299.77M | +47.6% | +34.8% | |
| LTM Dec 2025 | $115.91M | — | — | |
| LTM Mar 2026 | $88.24M | +383560.9% | +200.9% | |
| LTM Mar 2026 | $87.82M | -44.0% | +14.8% | |
| LTM Mar 2026 | $69.64M | +123.1% | +610.3% | |
| LTM Mar 2026 | $57.94M | -58.0% | -43.6% | |
| LTM Mar 2026 | $55.54M | -55.4% | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding GOSS) | $78.73M | +47.6% | +34.8% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| Weighted Avg Shares | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
| Weighted Avg Shares (Diluted) | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.